Search results for: France
Filter search results
The Impact of Behavioural and Biomedical Advance on Health Trends over the Next 25 Years
11 January 1994
…reports dealt with France, the former West Germany and the United Kingdom respectively (Andersson et al, 1992; Andersson etal, 1993; Oleksy etal, 1994). The US study was commissioned by the…
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
…often overlooked. Countries with more flexible HTA frameworks, like Canada and the UK, are better positioned to capture these broader value elements than others like Germany and France. Stakeholder collaboration…
Altering the trajectory of HIV in Europe
22 May 2025
…to rise, leading to increases in healthcare costs and broader societal impact. The total estimated cost of HIV care between 2025 and 2030 is estimated at €56.7bn across France, Germany,…
Patient preferences for treatment in relapsed/refractory acute leukemia
23 October 2025
Share this: Download publication David Mott Hannah Hussain Jake Hitch Sulayman Chowdhury Samantha Nier Chris Skedgel Key takeaways Across all five countries studied (UK, USA, France, Germany, and Italy), the…
Atherosclerotic cardiovascular disease (ASCVD) costs the world $680 billion a year in healthcare – roughly the size of Sweden’s entire economy, new research finds
31 March 2026
…insights into the health and economic costs of ASCVD across nine more-developed countries – the US, Canada, UK, Netherlands, France, Germany, Spain, Italy, and Japan. The researchers found that total costs associated with ASCVD range…
The value of fast diagnostics in time-critical infections
20 April 2026
…outcomes and reduce health system costs for adults hospitalised with bloodstream infections at high risk of progressing to sepsis. The analysis covers seven major health systems (Canada, France, Germany, Italy,…
One Europe, one assessment? Unpacking the European Joint Clinical Assessment
28 May 2026
…Germany and France, integration has been more explicit, including formal incorporation of JCA reports into national assessment procedures, reduced duplication of clinical evidence submissions, and increased alignment with EU-level dossier…
Germany’s drug-pricing dilemma: Why Europe’s pivotal market holds the key to the MFN debate
25 June 2026
…the Trump Administration asking it to launch Section 301 investigations into key markets including Germany, Japan, France, and Canada on drug pricing. USTR has now opened a docket, and this will…
How long are patients WAITing for new treatments?
2 July 2026
…France, Italy, Switzerland, the UK, and Denmark. All six report above-average rates of availability, with an average of 71%, compared to the overall sample average of 44%, as shown in…